How I Treat ALL: What Are the Best Treatments for Relapsed ALL?

Description

The prognosis of adult patients with acute lymphocytic leukemia (ALL) in first relapse is poor (less than 10 percent overall survival at five years), and better approaches are clearly needed. This session will review the novel agents that are either FDA approved (e.g., blinatumomab) or in clinical trials (e.g., CAR T cells and inotuzumab) in the treatment of relapsed disease.

Presenters

  • Anjali Advani

Pricing

Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top